Sophie Pierce is determined to make the most of her life - however long she may have.

Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

KIT-2014 is under development for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. The therapeutic candidate acts by targeting phosphoinositide 3-kinase gamma. It is ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...

An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...

Stockard has completed the interview portion of the competition and is now preparing for on-stage competition, which, for her ...

Giving back to the community is also a cornerstone of his life, as he actively supports organizations like the Cystic Fibrosis Foundation and the Make-A-Wish Foundation. "Helping others reminds me of ...

There was severe flooding in the Mid-Ohio Valley at the beginning of April that caused some businesses to go underwater. Two ...

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Sixteen-year-old Kaia Barret lays in a hospital bed for the third day in a row after suffering intense burns and<a ...